Jefferies Global Healthcare Conference
Logotype for Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals (CRVS) Jefferies Global Healthcare Conference summary

Event summary combining transcript, slides, and related documents.

Logotype for Corvus Pharmaceuticals Inc

Jefferies Global Healthcare Conference summary

16 Nov, 2026

Pipeline and mechanism

  • Soquelitinib, an oral selective ITK inhibitor, is in a Phase III registrational trial for relapsed/refractory PTCL and a Phase II atopic dermatitis trial; both are enrolling.

  • ITK inhibition blocks Th2 and Th17 signaling while sparing RLK, preserving Th1 activity; the proposed effect is immune rebalancing, including increased active Tregs, rather than broad immune suppression.

  • Reported binding affinity was KD 6.5 for ITK versus 2,700 for RLK; selectivity is intended to limit off-target effects, and clinical safety was described as comparable to placebo.

  • IP protection extends through November 2037, or 2042 with pharmaceutical extensions; HS enrollment began, and an asthma study is planned for early 2027.

Atopic dermatitis findings

  • In a 72-patient Phase I monotherapy study, the higher-dose, 8-week cohort showed EASI-75 of 75% versus 20% on placebo and IGA 0/1 of 33%.

  • Across cohorts, active treatment separated from placebo as early as week 2; responses were also observed among patients with prior systemic therapy and treatment-resistant patients.

  • EASI-75 responses persisted after treatment ended: the first three cohorts remained near 40% at 90 days off treatment, while the higher-dose cohort maintained response at 30 days off treatment.

  • Biomarkers showed reductions in IL-4, IL-5, IL-13 and TARC, plus increased Tregs that remained elevated off treatment; safety was described as favorable and comparable to placebo.

  • SIERRA1 is enrolling 200 adults across four cohorts, testing 200 mg QD, 200 mg BID and 400 mg QD versus placebo; results are planned for Q3 2027.

Other programs and 2027 milestones

  • The Phase III PTCL trial has a futility analysis planned for Q1 2027 and top-line data expected by year-end 2027; the program has orphan drug and fast track designations.

  • A Phase I-B HS proof-of-concept trial is enrolling up to 25 patients for 12 weeks; safety, HiSCR, IHS4 and skin and blood biomarkers will be assessed, with data expected in H1 2027.

  • The asthma trial is planned to start in early Q1 2027 and enroll both T2 and non-T2 patients, with interim assessment by group; Angel plans to initiate a China asthma trial in Q2.

  • Angel Pharmaceuticals, 49%-owned, is running a China AD study: cohort one data are expected in March 2027, and cohort two data in H2 2027; the partner may expand enrollment by 60–90 patients after Phase I-B.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Corvus Pharmaceuticals